FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Section 1	 Form 4 or ns may contin 	nger subject to Form 5 ue. See	STAT		oursuan	t to Sectio	n 16(a	a) of the Se	curiti	es Exchan	ige Act of	VNERS 1934	HIP	Estima	Number ated av per res	erage burden	0.5	
1. Name and Address of Reporting Person [*] Gall Matthew					2. Issuer Name and Ticker or Trading Symbol <u>iTeos Therapeutics</u> , Inc. [ITOS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) 321 ARSE	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/09/2023						,	X Officer (give title Other (specify below) below) Chief Financial Officer						
(Street) WATERTC (City)			02472 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. In Line	,						
		Та	ble I - Non	-Derivat	ive Se	ecuritie	s Ac	quired,	Disp	oosed o	of, or Be	neficially	Owned					
Date				2. Transact Date (Month/Day	Execution Date		e, Transaction Disposed C Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficial Owned Fo Reported	Form ly (D) o		Direct I Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) c (D)	r Price	Transaction(s) (Instr. 3 and 4)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Security of (Instr. 3) P D	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	0.1107			
Stock Option (Right to Buy)	\$16.66	03/09/2023		Α		130,000		(1)	0.	3/09/2033	Common Stock	130,000	\$0.00	130,00	00	D		

Explanation of Responses:

1. This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.

Remarks:

/s/ Adi Osovsky, as Attorney-in-03/10/2023

Fact ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.